Read More

This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential

AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform rating.

AZN

Read More

Wall Street Extends Record Highs Ahead Of Key Inflation Report, Bitcoin Hits $50,000, NVIDIA Surpasses Amazon: What’s Driving Markets Monday?

Wall Street kicked off the week on a high note, with the S&P 500 and Nasdaq 100 reaching new highs in anticipation of the January inflation report scheduled for this Tuesday.

AMZN

Read More

Cocoa Crunch, Pricing Woes – Morgan Stanley Flags Hershey’s Bitter Aftertaste, Downgrades Stock

Hershey faces stock downgrade as Morgan Stanley analyst cites concerns over mixed Q4 earnings and bleak midterm outlook amidst cocoa inflation and weakened consumer demand. Analyst Pamela Kaufman predicts input cost inflation and gross margin contraction, leading to lowered EPS estimates for 2025, despite Hershey's proactive measures and investment plans in innovation.

HSY